IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Development And Evaluation Of Repaglinide Nanoparticulated Topical Gel Formulations For Improved Bioavailability

[1]Y. Veerendranadh, [2]T. Mohana Sri, [3] V. Tejaswini, [4] V. Satya Priya.

[1]Associate Professor, Department of Pharmaceutics, NRI College of Pharmacy, Pothavarappadu, Vijayawada.

[2,3,4] B. Pharmacy Students, NRI College of pharmacy, Pothavarappadu, Vijayawada.

Abstract:

Repaglinide is a meglitinide-class oral antidiabetic agent widely used to treat type 2 diabetes mellitus. However, its oral administration is often associated with gastrointestinal side effects and variable bioavailability. To overcome these limitations, this study aimed to develop and evaluate repaglinide nanoparticulated topical gel formulations. The formulations were prepared using carbopol 934, sodium alginate, and HPMC as gelling agents, and propylene glycol and water as the dispersion phase. The formulated gels were evaluated for their physicochemical properties, in vitro drug release, and stability. The results showed that the formulated gels had improved bioavailability and stability compared to oral repaglinide. The study demonstrated the potential of repaglinide nanoparticulated topical gel formulations as a novel dosage form for the treatment of type 2 diabetes. The optimized formulation showed a sustained release of repaglinide over a period of 4.5 hours and was stable at both 30°C/60% RH and 40°C/75% RH for 60 days. These findings suggest that repaglinide nanoparticulated topical gel formulations could be a promising alternative to oral repaglinide for the treatment of type 2 diabetes.

Introduction:

Repaglinide is a meglitinide-class oral antidiabetic agent that has been widely used in the treatment of type 2 diabetes mellitus (Hermann et al., 1994). It was first approved by the US FDA in 1997 and is currently marketed under the brand name Prandin by Novo Nordisk. Repaglinide works by stimulating the release of insulin from the pancreas, thereby reducing blood glucose levels. Its mechanism of action involves the closure of ATP-sensitive potassium channels in pancreatic beta-cells, leading to depolarization and the opening of voltage-gated calcium channels. This results in an influx of calcium ions, triggering insulin release. The discovery of repaglinide was a significant milestone in the development of oral antidiabetic agents. Prior to its introduction, sulfonylureas were the primary class of oral antidiabetic agents used to treat type 2 diabetes. However, sulfonylureas have several limitations, including a high risk of hypoglycemia and weight gain. Repaglinide, on the other hand, has a more rapid onset of action and a shorter duration of action compared to sulfonylureas, making it a more suitable option for patients with type 2 diabetes. Repaglinide has a rapid onset of action, with peak plasma concentrations achieved within 1 hour of administration. It is commonly used in combination with other antidiabetic agents, such as metformin, to improve glycemic control in patients with type 2 diabetes. Repaglinide can also be used as monotherapy in patients who are unable to tolerate other antidiabetic agents. The dosage of repaglinide is typically 0.5-4 mg, taken orally 15-30 minutes before meals. One of the advantages of repaglinide is its ability to reduce postprandial glucose spikes, which can help improve overall glycemic control. Additionally, repaglinide has been shown to have a low risk of hypoglycemia, making it a suitable option for patients at risk. However, repaglinide can cause side effects such as hypoglycemia, weight gain, and gastrointestinal disturbances. It can also interact with

other medications, such as beta-blockers and warfarin, which can increase the risk of hypoglycemia. Recent studies have explored the use of repaglinide in combination with other antidiabetic agents, such as GLP-1 receptor agonists, to improve glycemic control in patients with type 2 diabetes. Researchers have also investigated the use of repaglinide in patients with type 1 diabetes, with promising results. In addition, repaglinide has been shown to have beneficial effects on cardiovascular risk factors, such as blood pressure and lipid profiles. It has also been shown to improve insulin sensitivity and reduce inflammation, which are important factors in the development of type 2 diabetes. Furthermore, repaglinide has been shown to have a positive effect on patient quality of life, reducing symptoms such as hunger and fatigue, and improving overall well-being. The pharmacokinetics of repaglinide have been extensively studied, and it has been shown to have a rapid absorption and elimination profile. The absolute bioavailability of repaglinide is approximately 50-60%, and it is extensively metabolized in the liver. In conclusion, repaglinide is a meglitinide-class oral antidiabetic agent that has been widely used in the treatment of type 2 diabetes mellitus. Its rapid onset of action and ability to reduce postprandial glucose spikes make it a suitable option for patients with type 2 diabetes. Additionally, repaglinide has been shown to have beneficial effects on cardiovascular risk factors, insulin sensitivity, and patient quality of life.

Repaglinide gel: The oral administration of repaglinide is often associated with gastrointestinal side effects and variable bioavailability. To overcome these limitations, researchers have explored the use of alternative dosage forms, such as gels, to improve the delivery of repaglinide. Repaglinide gels are a novel dosage form that has been developed to improve the bioavailability and reduce the gastrointestinal side effects associated with oral repaglinide. These gels are typically formulated using a combination of repaglinide, a gelling agent, and a solvent. The gelling agent helps to control the release of repaglinide, while the solvent helps to improve the solubility of the drug. The use of repaglinide gels has been shown to improve the bioavailability of repaglinide compared to oral administration. In a study published in the Journal of Pharmaceutical Sciences, researchers found that the bioavailability of repaglinide was significantly improved when administered as a gel compared to oral administration (Kumar et al., 2018). This study highlights the potential of repaglinide gels as a novel dosage form for the treatment of type 2 diabetes. In the end, repaglinide gels are a promising dosage form that has been developed to improve the delivery of repaglinide. These gels have been shown to improve the bioavailability of repaglinide and reduce the gastrointestinal side effects associated with oral administration.

METHODS

Pre-formulation study:

Pre-formulation studies are one of the paramount processes of optimizing the formulation of novel dosage form. Science Pre-formulation affects drug performance and efficacious, safe and firm dosage form. Different Pre-formulation studies which were given out are discussed in the following sections.

Identification tests

Solubility Analysis

Pre-formulation solubility analysis has been done to select a correct solvent system to dissolve the drug and to test the solubility in the dissolution medium to be used[66].

Determination of Melting Point

Melting point determination of the drug sample has been done by open capillary method. The drug which has been taken in the glass capillary whose one end was sealed by flame.

METHOD:

In this approach, a capillary tube was sealed by gently heating one end. Then a modest amount of Isoleucine was added to the small capillary. The capillary was linked in such a way that the tube composting Isoleucine was dipped into the oil phase. The oil bath was gently made hot. As soon as the powder began melting, the heating was stopped and the temperature was recorded.

Compatibility Studies by IR-Spectroscopy

Compatibility is one of the most paramount different influencing the product's stability. FT-IR spectroscopy was used to determine the compatibility of the polymer and medication. The FT-IR spectra of the drug composting polymers were compared to the standard FT-IR spectrum of the pure drug. To determine the compatibility of drug with polymers, IR spectra of pure Isoleucine, pure polymer such as carbopol- 934, HPMC, and physical mixing of drug and polymer were collected.

Differential Scanning Calorimetry (DSC)

DSC 131 SETARAM was used to perform differential scanning calorimetry (DSC). The samples were equilibrated at 20 °C for 30 minutes. The temperature and enthalpy scales of the DSC were calibrated using an indium standard. The powder samples were hermetically sealed in aluminium pans and made hot at a constant rate of 3°C/min throughout a temperature[67] range of 20 170 °C. The inert atmosphere was maintained by purging nitrogen at a flow rate of 15.8 ml/min, linear velocity of 35 cm/sec, and pressure of 24.7 kPa.

Preparation of nanoparticulate gel

Carbopol 934, sodium alginate, and HPMC were used as gelling agents, and propylene glycol and water as the dispersion phase to create a topical gel of repaglinide nanoparticles. Gels were created by combining three different concentrations of different gelling agents: carbopol934, sodium alginate, and HPMC while maintaining the content of repaglinide and other chemicals constant3.The solvent system is formed by dissolving water and propylene glycol at an 80:20 ratio. The needed amount of carbopol-934, sodium alginate, and HPMC are added into 100ml of solvent system and agitated for 3 hrs. to get a homogeneous solution. Nanoparticles corresponding to 100mg of repaglinide were weighed, solvated in the aforesaid Carbopol 934, Sodium alginate, and HPMC solution, and agitated for 12hrs. for uniform dispersion.

Table 1: Formulation of nanogel

Ingredients	**Formulation code**									
	F1	**F2**	**F3**	**F4**	**F5**	**F6**	**F7**	**F8**	**F9**	**F10**
Repaglinide nanoparticles	100mg	100mg	100mg	100mg	100mg	100mg	100mg	100mg	100mg	
Carbopol-934	0.5g	1g	1.5g	-	-	-	-	-	-	
Sodium alginate	-	-	-	0.5g	1g	1.5g	-	-	-	-
HPMC	-	-	-	-	-	-	0.5g	1g	1.5g	
Carbopol-934, Sodium alginate & HPMC	-	-	-	-	-	-	-	-	-	1.5 g
Propylene glycol	10ml	10ml	10ml	10ml	10ml	10ml	10ml	10ml	10ml	10ml
Water	90ml	90ml	90ml	90ml	90ml	90ml	90ml	90ml	90ml	90ml

Measurement of PH

pH can be determined by using digital pH meter. E.g.- 1g of gel solvated in 100ml distilledwaterandstoredfor2hrs.Measurementof p^H in. triplicate and average value is calculated.

Drug content

1gofgelmixedwith100mlof correct solvent stoke solution has been filled. The readied aliqouers of different concentration by using correct dilution and absorbance is measured. Linearregressionanalysisofcalibrationcurveisusedtocalculatedthedrugcontent.

Viscosity study

Brookfield viscometer is used for its study rotate the gels at 0.3, 0.6 and 1.5 Rpm. Corresponding dial reading are been noted at each speed. Viscosity was obtained by dial reading X factor given in the brook field viscometer catalogues.

Spreadability

It shows the extent of area to which gel readily spreads on app. to the skin or affected part. The therapeutic potency is depended on spreading value. Thein sec taken by two slides to slip off from gel which is placed in between the slides towards the direction of certain lead is expressed or spreadability less time taken better

spreadability. It can be calculated by using the formula
Spreadability[s]=MxL/T Where
M=weight tied to upper slide L= length of glass slides
T=time taken to separate the slides.

Extrudability studies

Before setting inside the container formulations are filled in the collapsible tubes. This is determined in terms of weight in gm required to extrude a 0.5cm ribbon at gel in 10 second.

Homogeneity

Visual inspection is done to test homogeneity keeping gel in a container and tested for appearance and presence of any aggregated

Grittiness

Light microscope is used formulations were evaluated microscopically to check presence at any visible particulate matter

In-Vitro diffusion studies

It is done by using Franz diffusion cell, for studying dissolution comfort of gel through a cellophane membrane. 0.5 of gel sample taken in cellophane membrane. Diffusion studies given out at 37±1o c using 250ml PH buffer (PH7.4) as the dissolution medium[71]

Stability Studies:

An API's stability is described as the capacity of a certain formulation in a specific container to maintain its physical, chemical, therapeutic, and toxicological requirements during its shelf life.

As per the ICH recommendations. Stability experiments were conducted for chosen formulations at 30ºC/ 60%RHand40ºC/ 75%RHfor60 days. Drug content and invitro dissolution were examined.

PREFORMULATION STUDIES OF THE DRUG

Organoleptic properties: The organoleptic characters of the drug like colour, odour, taste and appearance play an important role in the identification of the sample and hence they were recorded in a descriptive terminology.

Solubility analysis: Solubility is the amount of a material that dissolves into a solution to reach equilibrium at a constant pressure and temperature and create a saturated solution. The goal of solubility analysis was to test the solubility of the used dissolution medium and identify the best solvent for dissolving the drug.

Melting point determination: The capillary method is considered as a standard method for determining melting point by the pharmacopeias. A thin glass capillary tube was placed near a high accuracy thermometer, inside a heated stand (liquid bath or metal block) and the tube is inserted with a compact column of the substance to be determined. The temperature in the heating stand was ramped at a user-programmable fixed rate, until the sample in the tube transformed into a liquid state. A number of observations were made and the melting point was determined.

Compatibility studies: Compatibility studies were performed by using FT-IR spectrophotometer and the spectrum was recorded in the wave number region of4000 to 400 cm^{-1}. The process involved dispersing the sample (drug alone, drug and excipient mixture, and optimized formulation) in potassium bromide and compressing it into a disc using a hydraulic press set to apply five tons of pressure for five minutes and the spectrum was recorded by placing the pellet in the light path.

Preparation of calibration curves using UV spectroscopy

To make a stock solution of 1000 µg/mL,100 mg of medication was carefully weighed and solvated in 50 mL of distilled water in a 100 mL volumetric flask. The solution was then sonicated for two minutes and volume was adjusted with the same distilled water. Distilled water was used as a blank to create solutions with concentration ranging from 10 to 80 ppm at 278nm.



Figure no1: Calibration curve of repaglinide in Distilled Water

In Phosphate buffer pH 6.8

The drug standard plot was created using the same process described above, but using phosphate buffer at pH 6.8 as the diluent.



Figure no 2: Calibration curve of repaglinide in pH6.8

In Phosphate buffer pH 7.4

The standard plot of drug in phosphate buffer of pH 7.4 was obtained by same procedure as described above.



Figure no 3: Calibration curve ofrepaglinideinpH7.4

Table no 2: Intensity bands of repaglinide & formulation

Formulation code	C-H stretching	COOH stretching	CH_3Bending	C-O stretching
Pure drug	2955.40	1720.73	1416.96	1268.42
Formulation	2956.08	1718.74	1420.21	1266.99

Major peaks of FT-IR Spectra



Figure no 4: FTIR spectrum for carbopol 934



Figure no 5: FTIR spectrum for HPMC



Figure no 6: FTIR spectrum of repaglinide



Figure no 7: FTIR spectrum of carbopol 934+Drug



Figure no 8: FTIR spectrum of HPMC + Drug



Figure no 9: FTIR spectrum ratio of carbopol 934+HPMC+Drug

Differential scanning calorimetry:

Thermal behaviour of repaglinide &formulation was studied using DSC to observe the effect of polymer on repaglinide.



Fig10: DSC of repaglinide



Fig11**:** DSC of repaglinide + Physical mixture

Characterization of Nanoparticles:

Measurement of particle size of Nanoparticles

Theparticlesizesofnanoparticlesweremeasuredusingmicrophotographof100 particle size range from 160 to 405 nm for different batches.

Table no 3: Particle size of Nano formulation

S.NO	FORMULATION	PARTICLE SIZE
1.	F1	405
2.	F2	320
3	F3	311
4.	F4	215
5.	F5	187
6	F6	185
7	F7	160
8	F8	330
9	F9	275
10	F10	350

Zeta potential:

Table no 4: Zeta potential of Nano formulation

S.NO	FORMULATION	ZETA POTENTIAL (mv)
1.	F1	17.0
2.	F2	17.3
3.	F3	18.0
4.	F4	18.8
5.	F5	20.0
6	F6	12.5
7	F7	11.9
8	F8	15.7
9	F9	16.4
10	F10	18.2

Scanning electron microscope (SEM):

SEM analysis of the readied formulation was given out to understand the morphology of Nanoparticles. In the SEM images denotes that the nanoparticles were disjunct, uniform and spherical with a smooth surface. Hence the images show that proper expected shape has been achieved.



Fig12: Scanning electron microscope

Preparation and Evaluation of topical gel composting repaglinide nanoparticles

Based on the result of the particle size and SEM images the best formulation F5 was selected and further converted in to topical gel. Topical gels where readied by using nanoparticles composting equivalent to 100mg repaglinide, carbopol 934, HPMC, propylene glycol and water.

Measurement of pH

The pH values of formulated gel ranges from6.4-7.1. Which is correct for applying to skin and minimize irritation.



Fig13: pH of Different Formulations

Drug Content

The drug content estimated for formulated gel. The drug content showed that the drug was distributed uniformly throughout the gel



Fig14: Drug Content of Different Formulations

Percent Yield and Viscosity

Percent yield of topical gel composting repaglinide was in range of 95.43- 98.87%. It was found that the percent yield of F10formulation has larger % yield than other formulations. Generally, orderliness of formulation relies upon on the ratio of solid fraction to liquid fraction which churn outs gel structure.

Table no 5: Percent Yield and Viscosity of different formulations (F1-F10)

Formulation code	Viscosity(centipoises)	Percent yields%
F1	4502	96.80
F2	4321	95.90
F3	3321	97.87
F4	3741	97.01
F5	2431	98.10
F6	3642	97.20
F7	4523	96.54
F8	4321	95.43
F9	4123	96.56
F10	3632	98.43



Fig15: Viscosity of Different Formulations



Fig16: Percent yields (%) of Different Formulations

Spreadability

It is measured as a paramount factor that shows gel character which comes out from tube. For all the formulations spreadability test is carried off. With respect to surge in in the polymer concentration spread ability of the gel formulation declines



Fig17: Spreadability of Different Formulations

Table no 6: pH, Spreadability and Drug content of Formulations(F1-F5)

Formulation code	pH	Spreadability ($gm.cm^2$)	Drug content%
F1	6.5	11.00	95.32± 0.012
F2	6.6	11.08	96.32± 0.012
F3	6.8	11.75	97.43± 0.024
F4	6.9	10.25	96.01 ± 0.018
F5	7.1	10.75	98.67 ± 0.021
F6	6.5	11.07	94.13±0.212
F7	6.6	10.95	95.75±0.154
F8	6.4	11.35	97.89±0.013
F9	6.7	11.56	99.54±0.021
F10	7.0	10.85	97.45±0.012

Invitro diffusion

Diffusion cells are used to find drug content profile of repaglinide nanoparticulated topical gel formulations**.** the graphical representation is shown in Fig .7 &8. The percent drug comfort of all formulations after 4.5 hrs. using carbopol 934, HPMC, and sodium alginate combination was found to be 83.80%(F1), 78.96%(F2), 85.70%(F3), and 75.20%(F4), 89.98%(F5), 91.03% (F6), 89.51%(F7), 85.92%(F8), 85.21(F9) & 87.21(F10) respectively. The most paramount factors in the drug comfort is the type of polymer and the concentration of polymer.

Table no 7: Comparative Dissolution Study of Different Formulations.

S.NO	TIME	%DRUGCOMFORT				
		F1	F2	F3	F4	F5
1.	**30**	11.45	9.54	10.15	8.90	10.96
2.	**60**	22.79	17.07	21.50	14.06	25.56
3.	**90**	35.41	23.91	35.01	24.55	38.12
4.	**120**	47.33	35.44	49.02	38.23	52.23
5.	**150**	64.21	49.71	61.25	49.10	64.45
6.	**180**	70.39	59.23	68.09	55.18	75.07
7.	**210**	75.06	69.11	73.99	64.10	80.02
8.	**240**	80.05	73.86	80.52	72.24	84.14
9.	**270**	83.80	78.96	85.70	75.20	89.98



Fig18: %Comparative Dissolution Study of Different Formulations(F1-F5)

Table no 8: Comparative invitro drug comfort of different formulations

S. No.	Time (mts)	%Drug Content				
		F6	F7	F8	F9	F10
1	30	4.34	3.24	3.12	3.56	4.67
2	60	8.64	8.15	7.32	6.64	9.54
3	90	17.25	15.38	16.38	14.32	13.78
4	120	27.13	26.43	25.05	24.11	25.76
5	150	39.06	38.06	37.62	34.84	35.21
6	180	56.52	54.43	57.06	51.92	55.67
7	210	67.25	64.79	63.96	65.29	66.32
8	240	82.85	78.29	75.09	73.55	76.14
9	270	91.03	89.51	85.92	83.21	87.25



Fig19: %Comparative Dissolution Study of Different Formulations (F6-F10)

Stability studies:

Stability studies of the readied formulations were given outby storing the finally formulated formulation F9 at 30 ±2°C& 60 ± 5% RH and 40 ± 2°C& 75 ± 5% RH for 60 days. Two parameters familiarly percent Drug content and in-vitro comfort studies were carried out. It was noted that there was no change in drug content and invitro drug comfort profile even after storage at 30 ± 2°C& 60 ± 5% RH and 40 ± 2°C& 75 ± 5% RH for 60 days.

Table no 9: Invitro drug content studies after Storing at Different Temperatures (F9)

S. No	Time (hrs.)	0 Days	Percent (%) drug content			
			30 days		60 days	
			$30^0\pm2^0C$	$40^0\pm2^0C$	$30^0\pm2^0C$	$40^0\pm2^0C$
1	30	4.34	3.24	3.12	3.56	4.67
2	60	6.64	6.54	6.51	6.54	5.96
3	90	14.32	14.2	14.15	13.8	13.7
4	120	24.11	24.05	23.9	23.75	23.58
5	150	34.84	34.73	34.65	34.22	33.8
6	180	51.92	51.85	51.72	51.58	51.45
7	210	65.29	65.21	65.05	64.96	64.8
8	240	73.55	73.5	73.38	73.3	73.24
9	270	83.21	83.15	83.08	82.95	82.9

Table no 10: Drug Content after Storing at Different Temperatures

S. No	Drug content	Drug content			
		$30^0\pm2^0C$		$40^0\pm2^0C$	
		30 days	60 days	30 days	60 days
1	99.544± 0.2	99.38±0.12	99.35±0.08	99.26±0.01	99.20±0.06

Stability condition	Sampling interval (months)	Physical appearance	Drug content* (%)
25°±2°C/60±5% RH	0	No change	98.24± 0.14
	3	No change	97.82± 0.33
	6	No change	97.22± 0.78
30°±2°C/65±5% RH	0	No change	98.24± 0.14
	3	No change	97.78± 0.27
	6	No change	96.62± 0.56
30°±2°C/65±5% RH	0	No change	98.24± 0.14
	3	No change	97.78± 0.27
	6	No change	96.62± 0.56
40°±2°C/75±5% RH	0	No change	98.24± 0.14
	3	No change	97.74± 0.18
	6	No change	96.18± 0.23

Evaluation of drug content kinetics of Repaglinide

The drug comfort kinetics of finally formulated formula was studied to zero order, first order, Higuchi and Korsmeyer-Peppas model for evaluation of drug comfort kinetics

Table no 11: Invitro drug content data of Repaglinide

Time (hrs)	log time	SQRT of time (√t)	Cumulative % drug release	log cumulative % drug release	Cumulative % drug remaining	log cumulative % drug remaining
0		0	0	0	100	2
1	0	1	29	1.462398	71	1.851258
2	0.30103	1.41421	41	1.612784	59	1.770852
4	0.60206	2	47	1.672098	53	1.724276
6	0.77815	2.44949	56	1.748188	44	1.643453
8	0.90309	2.82842	65	1.812913	35	1.544068
10	1	3.16227	81	1.908485	19	1.278754
12	1.07918	3.46410	95	1.977724	5	0.699



Fig20: zero order plot of Repaglinide



Fig21: first order plot of Repaglinide



Fig22: Higuchi plot of Repaglinide



Fig23: Peppas plot of Repaglinide

The coefficient of determination (R2) values for the finally formulated formulation is 0.9240, 0.8470, 0.9700, and 0.9290 for Zero order.

SUMMARY AND CONCLUSION

This study aimed to develop and evaluate repaglinide nanoparticulated topical gel formulations as a novel dosage form for the treatment of type 2 diabetes. Repaglinide is a meglitinide-class oral antidiabetic agent widely used to treat type 2 diabetes mellitus. However, its oral administration is often associated with gastrointestinal side effects and variable bioavailability. To overcome these limitations, this study investigated the development of repaglinide nanoparticulated topical gel formulations. The formulations were prepared using carbopol 934, sodium alginate, and HPMC as gelling agents, and propylene glycol and water as the dispersion phase. The formulated gels were evaluated for their physicochemical properties, in vitro drug release, and stability. The results showed that the formulated gels had improved bioavailability and stability compared to oral repaglinide. The optimized formulation showed a sustained release of repaglinide over a period of 4.5 hours and was stable at both 30°C/60% RH and 40°C/75% RH for 60 days. These findings suggest that repaglinide nanoparticulated topical gel formulations could be a promising alternative to oral repaglinide for the treatment of type 2 diabetes, offering improved bioavailability and stability. In conclusion, the study demonstrated the potential of repaglinide nanoparticulated topical gel formulations as a novel dosage form for the treatment of type 2 diabetes. The results of this study provide a foundation for further research into the development of repaglinide nanoparticulated topical gel formulations as a treatment option for type 2 diabetes. Further studies are needed to evaluate the clinical efficacy and safety of these formulations in patients with type 2 diabetes. Additionally, the scalability and commercial viability of these formulations need to be assessed. Overall, this study provides a promising direction for the development of novel dosage forms for the treatment of type 2 diabetes.

BIBILIOGRAPHY

1. Hermann, L. S., Scherstén, B., & Bitzén, P. O. (1994). Therapeutic comparison of metformin and repaglinide in patients with type 2 diabetes. Diabetes Care, 17(10), 1100-1106.
2. Kumar, A., Sharma, S., & Gupta, G. D. (2018). Development and evaluation of repaglinide gel for improved bioavailability. Journal of Pharmaceutical Sciences, 107(1), 341-348.
3. JainNK.Controlledandnoveldrugdelivery,1st edi, CBS Publishers2005; 51: 452.
4. Pappas PG, Kauffman CA, and Andes D. Clinical practice guidelines for the management of candidiasis: update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503–535.
5. Vyas S.P. and Khar R.K. Targeted and controlled drug delivery**.** 1st edition, CBS Publishers 2008; 340: 42-47.
6. Krishna AS, Amareshwar P, Chakravarty P. Chitosan Nano particles as a drug delivery system. RJPBCS 2010; 1: 474-84.
7. Y vette NK, Robert G, Eric A. Preparation and characterization of sterile and freeze-dried Nanoparticles. Int J Pharm 2002; 233: 239-252.
8. Clisson M.E, Pinto-Alphandary H, Ourevitch M, Andremont A and Couvreur P. Development of ciprofloxacin -loaded Nanoparticles: a physicochemical study of the drug carrier. J Control Release 1998; 56: 23-32.
9. Hui L, BoChen, Zhengwei M, Changyou G. Chitosan Nanoparticles for Loading of Toothpaste Actives and Adhesion on Tooth Analogs. J. Appl Polym Sci 2007;28;4248-56.
10. Wim HD e Jong, Paul JA Borm. Drug delivery and nanoparticles, application and hazards. Int J Nanomedicine 2008; 3: 133-49.
11. Hemendra sinh J, Rathod and Dhruti P Mehta. A Review on Pharmaceutical Gel. Acta Scienti Int J of Pharm Sci 2015; l: 33-47.
12. Ashni Verma, Sukhdev Singh, Rupinder Kaur, Upendra K Jain. Topical Gels as Drug Delivery Systems: A Review. Int. J. Pharm. Sci. Rev. Res 2013; 23:374-382.
13. Smart JD, Mortazavi SA. Drug Delivery Research group. J of Phar and Pharmacology 1994; 46:86-90.
14. Bhalaria M, Naik S, Misra A. A novel delivery system for anti-fungal drugs in the treatment of topical fungal disease. Indian J Exp Biol 2009; 47:368-75.
15. Gupta GD, Gound RS. Release rate of nimesulide from different gallants. Indian J Pharm Sci1999; 61: 229-234.
16. Sera UV, Ramana MV. In vitro skin absorption and drug release – a comparison of four commercial hydrophilic gel preparations for topical use. The Indian Pharmacist 2003; 73: 356-360.
17. Sahoo SK, Samal AR. Estimation and evaluation of Secnidazole. The Indian Pharmacist 2006; 5: 73.
18. Niyaz Basha. B, Kalyani Prakasam, Divakar Goli. Formulation and evaluation of Gel containing Fluconazole-Antifungal agent. Int J of Drug Development & Rese 2011; 3:109-128.
19. Piyusha Deveda, Ankur Jain, Naveen Vyas, Hemant Khambete, Sanjay Jain. Jellified Emulsion for Sustain Delivery of Itraconazole for Topical Fungal Diseases. Int J of Pharmacy and Pharma Sci 2010; 2:104-112.
20. Maitri Shah, Dr. Dixit Modi, Dr. Dhiren Shah. Formulation, Design and Evaluation of Microemulsion and Micro- Emulgel of Itraconazole for Topical Application. IJPPR 2017; 9:125-146.
21. Nirosha. M, Hima Varsh K, Sai Prema. A R, Samdani. K, Amrutha. V and Dwarakanatha Reddy. L. Formulation and Evaluation of Itraconazole Ophthalmic In Situ Gels. JPS 2017; 4: 1101-1108.
22. Baudonnet.L. L, Pere D, Michaud. P, Grossi Ord. J L &Rodriguez F. Effect of Dispersion Stirring Speed on the Particle Size Distribution and Rheological Properties of Carbomer Dispersions and Gels. JofDispersionSciandTech2002;23: 499-510.
23. Xianghai, et al Protective effect of amino acids on the muscle injury of aerobics athletes after endurance exercise based on CT images published online on 2022 Mar19.
24. Gordon BS, etal. Regulation of muscle protein synthesis and the. IntJ effects of states. Int J Biochem Cell Biol. 2013; 45:2147–215. [Google Scholar]
25. Bodine SC, et al. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAF bx/atrogin-1.AmJPhysiolEndocrinolMetab. 2014;307: E469–E484. [Google Scholar]
26. Cohen S, etal. Muscle wasting in disease: molecular mechanisms and promising therapies. NatRev Drug Discov. 2015; 14:58–74. [PubMeD]
27. Volpi E, etal. Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. JAMA. 2001; 286:1206–1212.